Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Accounts Payable
Intercept Pharmaceuticals Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Accounts Payable
$10.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$31.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$622m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$351.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$671.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
23%
|
CAGR 10-Years
35%
|
See Also
What is Intercept Pharmaceuticals Inc's Accounts Payable?
Accounts Payable
10.3m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Accounts Payable amounts to 10.3m USD.
What is Intercept Pharmaceuticals Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
7%
Over the last year, the Accounts Payable growth was -52%. The average annual Accounts Payable growth rates for Intercept Pharmaceuticals Inc have been -13% over the past three years , 8% over the past five years , and 7% over the past ten years .